At Phosphorex, we understand the limitations of current therapeutic modalities, which often lack precise targeting capabilities. For instance, lipid nanoparticles administered systemically tend to accumulate predominantly in the liver, while delivering therapeutic cargos to immune cells, especially lymphocytes, remains challenging. That's where we step in to address these unmet needs.
Our Expertise and Solutions:
- Tissue Targeting: Through rigorous nanoparticle screening, we identify the optimal formulation for specific targeting needs, whether it's spleen, kidney, heart, lung, bone marrow, skin, or exclusive liver targeting for liver-related diseases
- Intra-cellular Delivery: By adjusting starting materials and formulation parameters, we optimize cell uptake and transfection, ensuring effective intracellular delivery of therapeutic agents
- Passive Targeting: Leveraging the Enhanced Permeability & Retention (EPR) Effect, our nano-sized particles accumulate in tumor tissue, delivering higher concentrations of anti-tumor agents to target sites
- Active Targeting: For maximum therapeutic impact, active targeting is essential. We chemically conjugate monoclonal antibodies, capable of binding specific cell surface receptors, to drug-loaded nanoparticles. This enables precise guidance of nanoparticles to the targeted site using conventional EDC chemistry and various "click chemistry" tools
- Sustained Release: Enhance patient compliance with long-acting, sustained release formulations that offer reduced dose frequencies and modified PK profiles. With over 15 years of expertise in developing long-acting microspheres, we specialize in formulating complex sustained release systems to transform APIs into effective therapeutic solutions
With over 15 years of experience, Phosphorex has been at the forefront of developing particle-based formulations for numerous biopharmaceutical companies. Our expertise spans a wide range of therapeutic and prophylactic applications, providing enabling solutions with significant therapeutic benefits.
Our Experience in Different Modalities:
Phosphorex specializes in particle-based formulations for diverse therapeutic applications. Our expertise spans various modalities, enabling significant advancements in therapeutic delivery.
- Ex-vivo Cell Therapy: LNPs deliver therapeutic cargos, like CAR, into lymphocytes for adoptive cell therapy (ACT).
- In-vivo Cell Engineering: LNPs facilitate targeted delivery and intracellular delivery of CAR for in vivo cell engineering.
- Gene Therapy: LNPs effectively load gene-editing agents, including CRISPR-Cas9, for gene therapy applications.
- Gene Silencing: LNPs, PNPs, and lipid-polymer hybrids deliver siRNA and ASO to silence pathogenic genes.
- Vaccines: LNPs deliver mRNA vaccines, including Covid-19 vaccines, and enable the loading of various antigens for cancer vaccines.
- Immuno-oncology: Nanoparticles enhance the delivery of immune-modulating agents to the tumor microenvironment (TME).
- Long-acting Injectables: Our biodegradable microspheres achieve sustained release of small molecules, peptides, and proteins.
Experiencing the different types of Payloads:
Phosphorex specializes in delivering diverse therapeutic payloads and achieving specific therapeutic effects through our range of particle formulations. We offer tailored solutions for various payloads, ensuring optimal performance and targeted delivery.
Our Payload Expertise:
- Nucleic Acid Payloads: DNA, mRNA, siRNA, and antisense oligonucleotides (ASO) find their ideal carriers in lipid nanoparticles (LNPs), maximizing their therapeutic potential.
- Small Molecules, Peptides, and Proteins: Biodegradable polymers form the foundation for our microspheres and nanoparticles, effectively encapsulating these payloads to enhance their performance.
- Other Formulations: Explore our wide array of formulations, including liposomes, micelles, nanocrystals, hydrogels, and their combinations, boosting the efficacy of active ingredients.
Targeted Delivery with Monoclonal Antibodies (mAbs):
Harness the power of mAbs as potent therapeutic and targeting agents. We have mastered the art of conjugating mAbs to the surface of both polymeric and lipid nanoparticles, ensuring precise and effective targeting.
Our Payload Expertise Includes:
- siRNA & ASO
- Small Molecules
- Monoclonal Antibodies (mAbs)
Our experience with Drug Carriers:
With 15+ years of experience, we have successfully developed and delivered drug carriers for a diverse range of therapeutic applications. Our team of experts works closely with clients to understand their unique needs, allowing us to develop tailored drug carrier solutions that meet specific requirements. Our extensive expertise in drug delivery systems sets us apart in the industry.
Our drug carrier expertise includes:
- Lipid Nanoparticles
- Polymeric Nanoparticles
- Polymeric Microspheres
- Lipid-polymer Hybrid